Hospira meets expectations with Q3 2012 fiscal performance

Hospira has expressed satisfaction with its financial performance for the third quarter of 2012, during which it experienced a year-on-year increase in sales.

The company's net sales total for the three-month period came to $994 million (625.44 million pounds), which was up by 1.8 percent compared to Q3 2011 and met Hospira's internal expectations.

Key priorities for the business at present include the advancement of quality improvement initiatives and an overall expansion strategy, with chief executive officer F Michael Ball stating he has been pleased with its progress in these areas.

The firm predicts that sales growth for the full year will range between minus one percent and two percent, factoring in the impact of foreign exchange rates.

Mr Ball said: "Our actions are positioning Hospira to be a stronger, more competitive global company, one that will serve the needs of our customers and patients and deliver strong value to our shareholders."

The company is among the world's leading providers of injectable drugs and infusion technologies and generated around $4.1 billion in sales last year.